Besic Nikola, Dremelj Marta, Schwartzbartl-Pevec Andreja, Gazic Barbara
Department of Surgery.
Department of Radiotherapy.
Radiol Oncol. 2015 Aug 21;49(3):271-8. doi: 10.1515/raon-2015-0001. eCollection 2015 Sep.
There is a paradigm that chemotherapy is ineffective in thyroid carcinoma. The aim of our study was to find out whether neoadjuvant chemotherapy before thyroid surgery had an effect on the size of primary tumour in patients with poorly differentiated thyroid carcinoma (PDTC) based on Turin proposal.
Altogether, 13 patients (8 women, 5 men; median age 61 years) with PDTC based on Turin proposal were treated with neoadjuvant chemotherapy between 1986 and 2005. Tumour diameter was from 4.5 to 18 cm (median 9 cm). Regional and distant metastases were detected in 6 and 9 patients, respectively. Eight patients had pT4 tumour.
Altogether, 29 (range 1-5) cycles of chemotherapy were given. Tumour diameter decreased in all the patients and by more than 30% in 5 patients (= 38%). Two of these five patients had also preoperative external beam irradiation (EBRT). Total thyroidectomy, lobectomy and neck dissection were performed in 10, 3 and 5 cases, respectively. R0 and R1 resection was done in 5 and 8 cases, respectively. Eight patients had postoperative EBRT of the neck and upper mediastinum. The 5-year and 10-year cause-specific survival rates of patients were 66% and 20%, respectively.
After neoadjuvant chemotherapy a partial tumour regression was observed in 38% of patients with PDTC based on Turin proposal.
有一种观点认为化疗对甲状腺癌无效。我们研究的目的是基于都灵提议,探究甲状腺手术前新辅助化疗对低分化甲状腺癌(PDTC)患者原发肿瘤大小是否有影响。
1986年至2005年间,共有13例基于都灵提议的PDTC患者(8例女性,5例男性;中位年龄61岁)接受了新辅助化疗。肿瘤直径为4.5至18厘米(中位值9厘米)。分别在6例和9例患者中检测到区域转移和远处转移。8例患者为pT4肿瘤。
总共进行了29个(范围1 - 5个)化疗周期。所有患者的肿瘤直径均减小,5例患者(= 38%)减小超过30%。这5例患者中有2例还接受了术前外照射放疗(EBRT)。分别有10例、3例和5例患者进行了全甲状腺切除术、甲状腺叶切除术和颈部淋巴结清扫术。R0切除和R1切除分别在5例和8例患者中进行。8例患者术后接受了颈部和上纵隔的EBRT。患者的5年和10年病因特异性生存率分别为66%和20%。
基于都灵提议,新辅助化疗后,38%的PDTC患者观察到肿瘤部分退缩。